Breast Cancer Detection Technology Licensed To Manhattan Scientifics Covered By Wall Street Journal

Technology Developed By Dr. Edward Flynn May Detect Cancer 2 1/2 Years Earlier Than Available Methods With Zero Radiation And Zero False Positives

March 2, 2011

Click here to view the printer friendly version of this press release

"potentially identify cancer cells more reliably and earlier than available methods."

ALBUQUERQUE, N.M.--Yesterday's Wall Street Journal (March 1) published a lead article on page D1 entitled “Researchers Create Better Ways To Spot Cancer Cells”, which described the research by Dr. Edward R. Flynn, of Senior Scientific LLC. The article was authored by Shirley S. Wang.

The WSJ article notes that Dr. Flynn’s early detection technology can "potentially identify cancer cells more reliably and earlier than available methods." The paper quoted Dr. Flynn’s belief that his technique appears to be much more sensitive than current methods and eliminates fear of radiation. Management added that the discomfort experienced with mammograms is also eliminated with Dr. Flynn's technology.

Current methods (Mammography) enable the detection of breast cancer only after tumors have reached 100 million malignant cells, whereas Dr.Flynn stated that his technology will see a breast cancer tumor with only 50,000 cells resulting in an estimated 2-1/2 year’s earlier detection. The article described Dr. Flynn’s technology, which involves the magnetic measurement of nanoparticles specifically targeted to cancer cells enabling disease detection far earlier than present day science.

The WSJ stated, "Dr. Flynn and his colleagues are working with nanoparticles to detect breast-cancer cells. The technique involves attaching nanoparticles of iron oxide to certain antibodies, which are then injected into the patient. If a tumor is present, the antibodies, with the nanoparticles in tow, naturally recognize and bind to the HER-2 receptor of breast-cancer cells." Flynn's breakthrough work in cancer has been funded by 9 grants from the National Institutes of Health (NIH) over an eight year period. His work is based upon experiments on human cancers on mice models. For more details please see and

The commercialization, responsibility and financing of this promising technology has been undertaken by Manhattan Scientifics Inc.(OTCBB:MHTX), a New Mexico based public company that specializes in bringing disruptive technologies to the market in partnerships with large well-financed entities. Manhattan Scientifics has entered into discussions with a variety of companies in the pharmaceutical and medical device industries. The Company filed patents covering early non-surgical detection, measurement and treatment of a variety of cancers, including; breast, ovarian, pancreatic, skin, cervical, brain, prostate, colon, and bladder.

About Manhattan Scientifics

Manhattan Scientifics, Inc. ( is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.